Dupixent Lawsuits Over Cancer Concerns To Be Grouped in Federal MDL
A group of Dupixent lawsuits has been given the green light for coordination in federal court. The U.S. Judicial Panel on Multidistrict Litigation (JPML) announced on Thursday that a multidistrict litigation (MDL) will be established for these cases, which claim Dupixent use is tied to a rare form of cancer.
MDLs are a common legal process used when many lawsuits over similar claims are filed in federal court. This places all of those cases before the same judge, where they can be coordinated and go through the legal process together. This can lead to faster and more uniform results for people with cases.
Lawsuits have been filed by people who claim they developed cutaneous T-cell lymphoma (CTCL) after using Dupixent. Other cases have been brought by spouses or family members of patients who died after developing the condition.
As many as 20 individual lawsuits are expected to be filed in the MDL right away, with many more cases expected to be grouped there in the coming months. The MDL was placed in New Jersey because Sanofi and Regeneron, the makers of Dupixent, have offices nearby.
Dupixent Lawsuits Claim Popular Drug Can Cause Rare, Devastating Cancer
Dupixent is a popular injectable medication used to manage conditions like atopic dermatitis and asthma.
Some users claim that they developed CTCL after using the drug. These concerns first emerged in 2024, when a study published in Dermatologic Therapy found that Dupixent users could be at a heightened risk of developing CTCL.
CTCL is a rare type of non-Hodgkin lymphoma that may first present with symptoms such as a rash or scaly patches on the skin.
Lawsuits claim that Regeneron and Sanofi failed to warn patients of this potential risk. The Dupixent label currently does not mention an increased risk of CTCL.
Lawyers are continuing to investigate and accept new cases from people who may have been impacted.